Evidence map›Paper›PMID 38107097›Full record

ReviewFood science & nutrition2023

A narrative review on the role of hesperidin on metabolic parameters, liver enzymes, and inflammatory markers in nonalcoholic fatty liver disease.

Nava Morshedzadeh, Amirhossein Ramezani Ahmadi, Vahideh Behrouz, Elias Mir

Open access · hybridAbstract readReview
In one paragraph

Review in Food science & nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Potential of Orally Administered Quercetin, Hesperidin, andInternational journal of molecular sciences · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Liver disorders and phytotherapy.Toxicology reports · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Mulberry andFood science & nutrition · 2024
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nava MorshedzadehStudent Research Committee Kerman University of Medical Sciences Kerman Iran.ORCID https://orcid.org/0000-0001-7765-8079
Amirhossein Ramezani AhmadiIsfahan Endocrine and Metabolism Research Center Isfahan University of Medical Sciences Isfahan Iran.ORCID https://orcid.org/0000-0003-2581-963X
Vahideh BehrouzDepartment of Nutrition, Faculty of Public Health Kerman University of Medical Sciences Kerman Iran.ORCID https://orcid.org/0000-0002-5625-6836
Elias MirStudent Research Committee Kerman University of Medical Sciences Kerman Iran.
Kerman University of Medical Sciences · IRIsfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance, oxidative stress, hyperlipidemia, and inflammation play main roles in the development of nonalcoholic fatty liver disease (NAFLD). Some studies have reported that hesperidin can reduce hyperglycemia and hyperlipidemia by inhibiting inflammatory pathways. In the current study, our purpose was to evaluate whether it can influence the primary parameters in NAFLD and improve the treatment effectiveness for future trials. Various studies have found that hesperidin involves multiple signaling pathways such as cell proliferation, lipid and glucose metabolism, insulin resistance, oxidative stress, and inflammation, which can potentially affect NAFLD development and prognosis. Recent findings indicate that hesperidin also regulates key enzymes and may affect the severity of liver fibrosis. Hesperidin inhibits reactive oxygen species production that potentially interferes with the activation of transcription factors like nuclear factor-κB. Appropriate adherence to hesperidin may be a promising approach to modulate inflammatory pathways, metabolic indices, hepatic steatosis, and liver injury.

Indexed as

fatty liverhesperidininflammationnonalcoholicobesity

Identifiers

PMID38107097
PMCPMC10724641
OpenAlexW4387541557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.